MHRA clears deuruxolitinib for severe alopecia areata in adults
The MHRA has approved deuruxolitinib (Leqselvi) for adults with severe alopecia areata, adding a new prescription option for a disease in which the immune system turns on the hair follicle itself. In alopecia areata, inflammation around the follicle interrupts normal hair cycling and can leave patients with patchy or near-complete loss of scalp hair, facial hair, or body hair. For many adults, the burden is not cosmetic alone. Hair loss can be persistent, visibly abrupt, and psychologically punishing, especially when the disease has already reached the severe end of the spectrum.
This approval places a JAK-pathway therapy into routine regulatory use in the UK, with the medicine intended for adults whose disease has already taken at least half of scalp hair and remained active for more than six months. The recommended dose is an 8 mg tablet taken twice daily. On the practical side, this is a simple oral regimen, but the biology behind it is more specific: deuruxolitinib reduces the activity of JAK1, JAK2 and TYK2 relative to JAK3 kinases, dampening inflammatory signaling at the hair follicle and allowing regrowth to resume.
Alopecia areata is driven by immune-mediated follicular injury, and the approval rests on a treatment model that directly addresses that pathway instead of merely masking the visible consequence.
Trial data tied hair regrowth to JAK inhibition
The decision was based on two pivotal clinical trials involving 1209 adult patients with alopecia areata and severe scalp involvement. Across both studies, participants were randomized to receive deuruxolitinib 8 mg twice daily, deuruxolitinib 12 mg twice daily, or placebo for 24 weeks. That design matters because it allowed regulators to compare two active dose strategies against an untreated control while keeping the follow-up period long enough to capture meaningful scalp regrowth rather than transient early change.
After 24 weeks, patients receiving Leqselvi scored higher on the scalp hair assessment scale than those assigned to placebo. The readout was not subtle. Around 30% of treated patients reached 80% or more scalp hair, and around 23% reached 90% or more scalp hair by week 24. For a condition defined by visible loss, those thresholds carry direct clinical meaning: they represent a shift from severe hair deficiency toward near-complete restoration in a meaningful subset of adults.
The mechanism is biologically coherent. Interfering with JAK-mediated inflammatory signaling should reduce the immune pressure at the follicular unit, and once that inflammatory brake eases, hair follicles can re-enter growth phases. In a disease where the target tissue is the hair follicle itself, the treatment logic is unusually direct.
Safety profile centers on headache and acne
The most common adverse effects listed for deuruxolitinib, each affecting more than 1 in 10 people, are headache and acne. Those reactions may sound modest next to the burden of severe alopecia, but they remain clinically relevant because chronic therapy often turns tolerability into the factor that determines whether patients stay on treatment long enough to benefit. The approval notice also states that the medicine will remain under close review, and the MHRA has placed it under additional monitoring so new safety information can be identified quickly.
This is a cautious posture, and for good reason. JAK-pathway drugs require ongoing safety surveillance because immune signaling sits close to several biologic systems rather than one isolated tissue. The agency’s decision to keep the medicine under close review reflects that broader pharmacologic reality. Patients who suspect side effects are advised to speak with their doctor, pharmacist or nurse and report concerns through the Yellow Card scheme.
What the approval means at the bedside
For adults living with severe alopecia areata, the approval creates another oral option that can be prescribed in the UK after regulatory review through the International Recognition Procedure. Sun Pharma UK Limited received the approval on 10 March 2026, and the product information is expected to appear on the MHRA Products website within seven days of approval.
The clinical implication is straightforward: dermatology now has one more systemic tool for a condition that can be stubborn, relapsing and difficult to manage once substantial hair loss has already occurred. In practice, patients with severe disease often need treatments that can suppress the immune attack long enough for visible regrowth to occur. An oral agent with a defined mechanism and measurable regrowth outcomes offers a clearer therapeutic path than watchful waiting alone.
Still, the trial duration was 24 weeks, and that leaves important questions about durability outside the controlled study window. Hair regrowth that appears by six months does not by itself define long-term remission, and sustained benefit will depend on continued treatment, ongoing safety monitoring and real-world adherence. The MHRA’s additional monitoring requirement signals that the benefit-risk balance will continue to be tracked after approval, not simply assumed from the trial period.
Adults with severe alopecia areata now have access to a therapy that aims at the inflammatory machinery driving the disease rather than only responding to its cosmetic consequences. The remaining challenge is to see how well that mechanism holds up in routine practice, where long-term tolerability and persistence matter as much as the initial regrowth signal.